Survodutide achieves 16.6% weight loss over 76 weeks

Boehringer Ingelheim and Xyvea's dual GLP-1/glucagon agonist survodutide showed 16.6% weight reduction in 76-week phase 3, data locked April. NIH separately published how oral small-molecule GLP-1s penetrate deep brain reward circuits to suppress appetite. Medicare begins $50/month GLP-1 options in July.